Pharmicell Co (XKRX:005690) Total Liabilities : ₩12,825 Mil (As of Dec. 2024)

View and export this data going back to 1988. Start your Free Trial

What is Pharmicell Co Total Liabilities?

Pharmicell Co's Total Liabilities for the quarter that ended in Dec. 2024 was ₩12,825 Mil.

Pharmicell Co's quarterly Total Liabilities increased from Jun. 2024 (₩8,458.92 Mil) to Sep. 2024 (₩9,155.23 Mil) and increased from Sep. 2024 (₩9,155.23 Mil) to Dec. 2024 (₩12,825.15 Mil).

Pharmicell Co's annual Total Liabilities declined from Dec. 2022 (₩32,982.27 Mil) to Dec. 2023 (₩12,121.81 Mil) but then increased from Dec. 2023 (₩12,121.81 Mil) to Dec. 2024 (₩12,825.15 Mil).

Pharmicell Co Total Liabilities Historical Data

The historical data trend for Pharmicell Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmicell Co Total Liabilities Chart

Pharmicell Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

12,639.17

30,461.55

32,982.27

12,121.81

12,825.15

Pharmicell Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															12,121.81	13,915.82	8,458.92	9,155.23	12,825.15

Pharmicell Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Pharmicell Co's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7645.983	+	(427.303	+	298.987
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	4452.874	+	0)
	=	12,825

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	99264.317	-	86439.17
	=	12,825

Pharmicell Co's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7645.983	+	(427.303	+	298.987
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	4452.874	+	0)
	=	12,825

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	99264.317	-	86439.17
	=	12,825

Pharmicell Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Pharmicell Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmicell Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmicell Co Ltd (XKRX:005690) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

12F Chungho B/D, 3-2 Nonhyun-dong Gangnam-gu, Seoul, KOR, 135-010

Website

http://www.pharmicell.com

Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

Pharmicell Co Headlines

No Headlines